Vir Biotechnology Stock News

H.C. Wainwright has raised the Vir Biotechnology Inc (NASDAQ:VIR) price target to $200 from $135, suggesting an upside of 330%. Analyst Patrick Trucchio reiterates a Buy rating on the stock.

NEW YORK, Nov. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VIR, NVAX, AMAT, PFE, and CRM. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different…

Vir Biotechnology Inc. (NASDAQ:VIR) traded at $41.19 at last check on Monday, November 29, made an upward move of 14.40% on its previous days price. Looking at the stock we see that its previous close was $36.00 with the days price range being $35.97 $38.34. In terms of its 52-week price range, VIR has Vir Biotechnology Inc. (NASDAQ: VIR) Jumps 14.40%, Turning Investors Away Read More »

With all eyes on the pandemic once again, these biotech players could be gaining more exposure.

Investors are looking to capitalize on the latest curveball thrown by the coronavirus contagion.

Two sample Breakout Stocks for Week 48 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Daily Momentum Gauges® the port

Vir Biotechnology, Inc. (NASDAQ:VIR) gapped up before the market opened on Friday . The stock had previously closed at $32.02, but opened at $35.43. Vir Biotechnology shares last traded at $37.02, with a volume of 18,167 shares. VIR has been the subject of several analyst reports. JPMorgan Chase & Co. upgraded Vir Biotechnology from an []

VIR's sotrovimab is a monoclonal antibody that binds to a highly conserved domain on the SARS-COV2 virus. The emergence of the South African variant has shown why mAbs are still highly relevant to tre

Equities research analysts expect Vir Biotechnology, Inc. (NASDAQ:VIR) to announce sales of $152.16 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Vir Biotechnologys earnings, with the lowest sales estimate coming in at $124.21 million and the highest estimate coming in at $180.10 million. Vir Biotechnology reported sales of []

NEW YORK , Nov. 26, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VIR, BNTX, CARS, TDOC, and PFE. Full story available on Benzinga.com

Black Friday Turns Red On "Terrible News" - Global Markets Crater On "Nu Variant" Panic The Friday after thanksgiving is called black Friday because that''s when retailers finally turn profitable for the year. Not so much for market, however, because this morning it''s red as far as the eye can see. The culprit: the same one we discussed late last night - the emergence of a new coronavirus strain detected in South Africa, known as B.1.1.529, which reportedly carries an "extremely high number" of mutations and is “clearly very different” from previous incarnations, which may drive further waves of disease by evading the body’s defenses according to South African scientists, and soon, Anthony Fauci. British authorities think it is the most significant variant to date and have hurried to impose travel restrictions on southern Africa, as did Japan, the Czech Republic and Italy on Friday. The European Union also said it aimed to halt air travel from the region. "Markets have been quite complacent about the pandemic for a while, partly because economies have been able to withstand the impact of selective lockdown measures.

Related Stocks: SPYG , SPYV , SCHG , VEA , VO , IJR , FCTR , DFAT , DFAI , IYW , DEN , WFHY , VIG , BGLD , PTON , KMB , GOVT , MTUM , MRVI , 41W0 , DNL , QDEF , VIR , WKHS ,

Equities research analysts forecast that Vir Biotechnology, Inc. (NASDAQ:VIR) will post earnings of $0.90 per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Vir Biotechnologys earnings, with the highest EPS estimate coming in at $4.52 and the lowest estimate coming in at ($0.99). Vir Biotechnology posted []